A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes.

Benjamin D PowersLuke D RothermelJason B FlemingJonathan R StrosbergDaniel A Anaya

Published in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2019)

Although OS is superior in surgically treated stage I PNETs, CSS is not improved, implying treatment selection bias towards surgery being performed in healthier patients. These data suggest that overall survival is a problematic endpoint for the study of asymptomatic, stage I PNETs. Surgery should be individualized for this cohort of patients as the primary cause of death is non-cancer related.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
minimally invasive
chronic kidney disease
neuroendocrine tumors
coronary artery bypass
type diabetes
metabolic syndrome
patient reported outcomes
electronic health record
big data
deep learning
artificial intelligence
replacement therapy